Dabur receives ‘no adverse observations’ from BSE on Sesa Care merger

Local FMCG firm Dabur on Friday said it has received an observation letter from BSE with “no adverse observations” on its plan to merge Sesa Care.

Local FMCG firm Dabur on Friday said it has received an observation letter from BSE with “no adverse observations” on its plan to merge Sesa Care.

“We would like to inform you that the company has received an observation letter dated December 4, 2025 from BSE Limited (“BSE”) with ‘no adverse observations’,” Dabur said in a regulatory filing.

An observation letter from the BSE is a formal document issued to a listed company, usually regarding a significant corporate action such as a merger, consolidation or restructuring, stating the exchange’s review and “no adverse observations” on the proposed scheme, allowing the company to proceed to the next regulatory step.

“The scheme is subject to various statutory and regulatory approvals and may be required by the respective shareholders and creditors of the companies involved in the scheme,” Dabur said.

Dabur acquired a majority stake in Sesa Care in October 2024 and a full merger plan of Sesa Care with Dabur was approved by its board in May 2025.

Sesa is a leading brand in the Ayurvedic hair care market with strong brand equity.